|
시장보고서
상품코드
2102127
산후 우울증 시장 규모, 점유율, 성장 분석 : 치료법별, 약물 계열별, 투여 경로별, 유통 채널별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Postpartum Depression Market Size, Share, and Growth Analysis, By Treatment Type (Pharmacotherapy, Psychotherapy), By Drug Class, By Route of Administration, By Distribution Channel, By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 산후 우울증 시장 규모는 2024년에 42억 1,000만 달러로 평가되었으며, 2025년 46억 8,000만 달러에서 2033년까지 109억 5,000만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 11.2%로 성장할 것으로 전망됩니다.
세계 산후 우울증(PPD) 시장은 출산 후 발생하는 우울증 에피소드의 진단 및 치료를 목적으로 하는 의약품, 디지털 치료제 및 지원 서비스로 구성되어 있습니다. 산모 약 7명 중 1명이 이 질환을 앓고 있는 것으로 알려져 있으며, 생산성 저하로 인해 이 질환은 막대한 경제적 부담을 초래하고 있습니다. 이전에는 제네릭 항우울제가 주류를 이루며 시장이 세분화되어 있었으나, 인지도 향상과 역학 연구를 통해 선별 검사 및 진단이 강화되면서 시장은 진화를 거듭하고 있습니다. 디지털 헬스 솔루션의 부상은 확장 가능한 치료 옵션을 가능하게 하는 중요한 동향입니다. 의료 서비스 제공자들이 보험 급여를 목적으로 원격 정신건강 진료를 도입하는 가운데, 스타트업 기업들은 AI 도구를 활용하여 위험 요인을 조기에 파악하기 위해 노력하고 있습니다. 또한, 제약사들은 디지털 플랫폼과 제휴하여 복약 순응도 모니터링 앱을 도입함으로써, 환자의 접근성을 높이고 시장 성장을 촉진하는 협업 생태계를 구축하고 있습니다.
세계 산후 우울증 시장의 성장요인
세계 산후 우울증 시장은 이 질환의 조기 발견을 촉진하기 위한 인식 제고 및 계몽 활동의 영향을 크게 받고 있습니다. 적극적인 선별 검사 프로그램이 등장함에 따라 산모들이 장기적인 영향을 완화하기 위한 시기적절한 치료적 개입을 받을 수 있게 되었습니다. 의료 종사자들은 산후 관리에 정기적인 정신건강 평가를 도입하여, 산모가 증상에 대해 부담 없이 상담할 수 있는 지원적인 환경을 조성하고 있습니다. 이러한 인식 제고는 환자의 건강 상태 개선으로 이어질 뿐만 아니라, 다양한 진단 도구, 상담 서비스 및 약물 선택지에 대한 수요도 높이고 있습니다. 그 결과, 전문적인 치료 경로의 이용과 수용이 확대되면서 시장 성장이 촉진되고 있습니다.
세계 산후 우울증 시장의 제약요인
세계 산후 우울증 시장은 여전히 뿌리 깊은 사회적 편견과 정신건강에 대한 깊게 고착된 문화적 오해로 인해 큰 과제에 직면해 있습니다. 많은 여성들은 산후 우울증 증상을 인식하고 인정하는 데 어려움을 느끼며, 도움을 요청하는 것이 개인적인 실패로 여겨질까 봐 두려워하는 경우가 많습니다. 이는 고립이나 치료받지 못한 상태로 이어져, 치료적 개입, 상담 서비스, 약물 치료에 대한 접근을 현저히 제한하고 있습니다. 게다가 종합적인 지역사회 인식 제고 활동의 부재가 이러한 불안을 증폭시켜, 산모의 정신건강에 대한 솔직한 소통을 저해하고 있습니다. 그 결과, 이러한 요인들이 복합적으로 작용하여 시장 성장을 저해하고, 필요한 지원 및 치료에 대한 전반적인 수요를 감소시키고 있습니다.
세계 산후 우울증 시장 동향
세계 산후 우울증 시장에서는 원격의료 및 모바일 헬스 솔루션에 대한 수용도가 높아지는 것을 배경으로, 디지털 치료법 도입을 향한 뚜렷한 추세가 나타나고 있습니다. 임상의들은 인지행동치료, 기분 추적, 동료 지원을 제공하는 근거 기반의 앱 주도적 중재를 점점 더 많이 도입하고 있으며, 이를 통해 환자의 참여도를 높이고 지리적 장벽을 제거하고 있습니다. 이러한 혁신적인 플랫폼은 고급 데이터 분석을 통해 맞춤형 치료 경로를 가능하게 하여, 환자 개개인에 맞춘 치료 접근 방식을 촉진하고 있습니다. 규제 체계가 ‘의료기기로서의 소프트웨어(SaM)’ 승인을 포함하도록 조정됨에 따라, 의료 서비스 제공자들은 가상 진료 솔루션의 안전성과 유효성에 대한 신뢰를 더욱 굳혀가고 있으며, 그 결과 시장 기회가 확대되고 영향을 받는 사람들이 더 쉽게 접근할 수 있게 되었습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 산후 우울증 시장 규모 : 치료 유형별
세계의 산후 우울증 시장 규모 : 약물 계열별
세계의 산후 우울증 시장 규모 : 투여 경로별
세계의 산후 우울증 시장 규모 : 유통 채널별
세계의 산후 우울증 시장 규모 : 최종사용자별
세계의 산후 우울증 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.08.03Global Postpartum Depression Market size was valued at USD 4.21 Billion in 2024 and is poised to grow from USD 4.68 Billion in 2025 to USD 10.95 Billion by 2033, growing at a CAGR of 11.2% during the forecast period (2026-2033).
The global postpartum depression (PPD) market encompasses pharmaceuticals, digital therapeutics, and support services designed to diagnose and treat depressive episodes occurring after childbirth. With approximately one in seven mothers affected, the condition poses a significant economic burden due to productivity losses. Previously characterized by a fragmented landscape dominated by generic antidepressants, the market has evolved as increased awareness and epidemiological studies prompted enhanced screening and diagnosis. The rise of digital health solutions is a pivotal trend, facilitating scalable treatment options. As healthcare providers embrace tele-psychiatry for reimbursement, startups are leveraging AI tools for early risk identification. Additionally, pharmaceutical companies are partnering with digital platforms to incorporate adherence monitoring apps, creating a collaborative ecosystem that improves patient access and market growth.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Postpartum Depression market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Postpartum Depression Market Segments Analysis
Global postpartum depression market is segmented by treatment type, drug class, route of administration, distribution channel, end user and region. Based on treatment type, the market is segmented into pharmacotherapy, psychotherapy, neuromodulation therapy and combination therapy. Based on drug class, the market is segmented into selective serotonin reuptake inhibitors (SSRIs), neuroactive steroids, serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs) and others. based on route of administration, the market is segmented into oral, intravenous (IV) and intranasal. based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. based on end user, the market is segmented into hospitals, specialty clinics, ambulatory care centers and home care settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Postpartum Depression Market
The Global Postpartum Depression market is significantly influenced by heightened awareness and education initiatives aimed at promoting early identification of the condition. Proactive screening programs have emerged, enabling mothers to receive timely therapeutic interventions that mitigate long-term effects. Healthcare professionals are incorporating routine mental health evaluations into postnatal care, creating a supportive atmosphere where mothers feel comfortable discussing their symptoms. This increased visibility not only leads to better health outcomes for patients but also boosts the demand for various diagnostic tools, counseling services, and medication options. Consequently, this fosters market growth through greater utilization and acceptance of specialized treatment pathways.
Restraints in the Global Postpartum Depression Market
The global postpartum depression market faces significant challenges due to ongoing societal stigma and deeply ingrained cultural misconceptions regarding mental health. Many women find it difficult to recognize and admit symptoms of postpartum depression, often fearing that seeking help may be perceived as a personal failing. This leads to isolation and untreated conditions, severely limiting access to therapeutic interventions, counseling services, and pharmaceutical treatments. Furthermore, the lack of comprehensive community education initiatives amplifies these fears, stifling open communication about maternal mental health. Consequently, these factors collectively hinder the market's growth and decrease the overall demand for necessary support and treatments.
Market Trends of the Global Postpartum Depression Market
The Global Postpartum Depression market is witnessing a significant trend toward the adoption of digital therapeutics, propelled by the increasing acceptance of telehealth and mobile health solutions. Clinicians are increasingly incorporating evidence-based app-led interventions that offer cognitive-behavioral therapy, mood tracking, and peer support, enhancing patient engagement and eliminating geographical barriers. These innovative platforms enable personalized treatment pathways through advanced data analytics, fostering a tailored approach to care. As regulatory frameworks adapt to include software-as-medical-device approvals, healthcare providers are gaining confidence in the safety and efficacy of virtual care solutions, leading to expanded market opportunities and improved accessibility for affected individuals.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Postpartum Depression Market Size by Treatment Type & CAGR (2026-2033)
- Market Overview
- Pharmacotherapy
- Psychotherapy
- Neuromodulation Therapy
- Combination Therapy
Global Postpartum Depression Market Size by Drug Class & CAGR (2026-2033)
- Market Overview
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Neuroactive Steroids
- Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
- Tricyclic Antidepressants (TCAs)
- Others
Global Postpartum Depression Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Oral
- Intravenous (IV)
- Intranasal
Global Postpartum Depression Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Postpartum Depression Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Specialty Clinics
- Ambulatory Care Centers
- Home Care Settings
Global Postpartum Depression Market Size & CAGR (2026-2033)
- North America (Treatment Type, Drug Class, Route of Administration, Distribution Channel, End User)
- US
- Canada
- Europe (Treatment Type, Drug Class, Route of Administration, Distribution Channel, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Treatment Type, Drug Class, Route of Administration, Distribution Channel, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Treatment Type, Drug Class, Route of Administration, Distribution Channel, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Treatment Type, Drug Class, Route of Administration, Distribution Channel, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Sage Therapeutics Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biogen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Viatris Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lupin Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hikma Pharmaceuticals PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alkem Laboratories Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Torrent Pharmaceuticals Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zydus Lifesciences Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
